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The TNF receptor superfamily (TNFRSF) comprises ∼30 genes whose products are Type I transmembrane glycoproteins ([@bib18]). Receptor occupancy by the corresponding TNF-like ligands affects a host of biological processes, including innate and adaptive immunity, cell death versus survival (homeostasis), and lymphoid development. Receptor engagement results in the assembly of signaling complexes that include enzymes that are also adaptors, one example of which is TNF receptor-associated factor 2 (TRAF2), a RING-containing ubiquitin protein ligase (E3) that recruits cellular inhibitors of apoptosis (cIAP) 1 and 2 to the signaling complex ([@bib9]). cIAP1 and cIAP2 themselves are RING-containing E3s ([@bib21]), and the interplay between these two protein families and other molecules in the receptor complex is critical in the propagation of downstream signals.

It has recently been appreciated that acute down-regulation of cIAPs is fatal for some tumor cell lines. Smac/DIABLO is a mitochondrial protein that, in stressed cells, is released into the cytosol and binds BIR (Baculovirus IAP repeat) domains of IAPs such as XIAP, displacing active caspases ([@bib12]). Based on the notion that the freed caspases would kill the cell, several groups have created IAP antagonists: small peptides or compounds that, like Smac, bind IAPs and interfere with caspase interaction. Although the IAP antagonists indeed did kill some tumor cell lines, the mechanism of action was completely unexpected ([@bib4]; [@bib8]; [@bib14]; [@bib16]). In sensitive cells, the IAP antagonists caused autoubiquitination and proteasomal degradation of cIAP1 and cIAP2 rather than the expected target, XIAP. Acute reduction in these IAPs activated both the canonical and noncanonical NF-κB pathways and caused autocrine TNFα production, which in turn led to TNFR1 occupancy, caspase-8 activation, and cell death. Because most cells lines are insensitive to killing by TNFα in the absence of a sensitizing agent such as cycloheximide, it was a logical inference that the IAP antagonists must also confer sensitization to exogenous TNFα, which proved to be the case.

TNF-like weak inducer of apoptosis (TWEAK; *TNFSF12*) was described in 1997 ([@bib2]), and its receptor, the non--death domain--containing TNFRSF member FGF-inducible 14-kD protein (FN14), in 2001 ([@bib19]). FN14 occupancy leads to TRAF2-dependent activation of MAP kinases and the canonical and noncanonical NF-κB pathways ([@bib10]). Like many TNF family members, TWEAK has roles that vary among tissues, including enhancement of proliferation, cell migration, expression and secretion of proinflammatory molecules, and proangiogenic activity ([@bib20]). As its name suggests, TWEAK was originally found to be a rather poor cytotoxic agent that killed a restricted number of tumor cell lines, usually in conjunction with a sensitizing agent. It has been difficult to pigeonhole a mechanism of action because cell death is mediated by different pathways in different cell lines, with the mechanisms including caspase-dependent apoptosis, cathepsin B--dependent necrosis, and indirect induction of apoptosis by induction of autocrine TNFα production ([@bib11]; [@bib7]).

In this issue of *The Journal of Cell Biology*, [@bib15] (see p. 171) explore the consequences of TWEAK-FN14 signaling in human tumor cells and find some unexpected similarities (as well as key differences) between TWEAK and IAP antagonists. Their initial observation was that a high proportion of tumor cell lines express FN14. Consistent with previous yeast two-hybrid and GST-FN14 pulldown studies, pulldown of FN14 with a TWEAK-Fc receptor fusion protein also brought down TRAF2 and cIAP1 from tumor cell lysates, the latter probably brought into the complex by TRAF2. Things began to get interesting with the observation that TWEAK signaling caused a gradual reduction of cIAP1, as previously noted ([@bib14]), and TRAF2, and although both molecules have E3 activity neither were rescued by proteasome inhibitors. Rather, lysosomal inhibitors such as chloroquine, ammonium chloride, and a selective cathepsin B inhibitor prevented TWEAK-induced TRAF2 and, to a lesser extent, cIAP1 degradation. This was sufficiently reminiscent of the behavior of IAP antagonists to ask if TWEAK-induced NF-κB activation is a consequence of cIAP1--TRAF2 loss. Several lines of evidence suggest that it is. First, both cIAP1- and TRAF2-deficient transformed MEFs had low constitutive levels of cytoplasmic p100 and high levels of nuclear p52 and higher levels of phosphorylated IκB and p65, indicating activation of noncanonical and canonical NF-κB pathways, respectively. In agreement with the IAP antagonist data, the enhanced noncanonical pathway was caused by stabilization of the p100-phosphorylating kinase NIK. How the canonical pathway was activated is unclear, but if the analogy with IAP antagonists holds, it may be caused by recruitment of RIP to preassembled TNF-R1 (TNF receptor 1) trimers ([@bib1]; [@bib15]). Second, enforced expression of TRAF2 and cIAP1, but neither alone, attenuated TWEAK-induced NF-κB activation. Further establishing a link with IAP antagonists, TWEAK stimulation of susceptible tumor cells caused NF-κB--dependent TNFα production and TNF-R1/caspase-8--dependent death, and TWEAK sensitized both long-term tumor lines and early-passage primary human tumors to killing by exogenous TNFα. Primary cells were resistant to TWEAK/TNFα cytotoxicity despite the fact that cIAP1--TRAF2 levels were reduced and NF-κB was activated just as in transformed cells.

Therefore, despite differences in the mechanistic details, there are remarkable similarities between stimulation with TWEAK and with IAP antagonists. One leitmotif is that the activation of NF-κB pathways and TNFα production stems from a reduction in cIAP1 and, in some cases, cIAP2 and TRAF2, a condition that can be termed cIAP deficiency (cIDE). Another is that cIDE sensitizes tumor cells to the cytotoxic effects of TNFα alone. It is interesting in this light to reconsider the observation that TNF-R2 signals for cIAP1 autoubiquitination and ubiquitination of TRAF2, their proteasome-mediated degradation, and sensitization of otherwise resistant cells to TNFα alone ([@bib6]). Prevention of autoubiquitination with an E3-defective cIAP1 mutant inhibited TNFα-induced TRAF2 degradation and cell death, demonstrating that in fact self-induced loss of cIAP1 and, perhaps, TRAF2 is proapoptotic. Reinforcing the similarities between these three stimuli, ligation of TNF-R2 (as well as the TNFRSF members CD30 and CD40) caused autocrine TNFα production and TNF-R1--dependent death in a tumor cell line also susceptible to IAP antagonists and TWEAK ([@bib5]).

The following is a simplified framework that deals with elements common to signaling by IAP antagonists, TWEAK/FN14, TNFα/TNF-R2, and perhaps other TNFRSF members ([Fig. 1](#fig1){ref-type="fig"}). In this model, cIDE activates the canonical NF-κB pathway by allowing RIP to associate with preassembled TNF-R complexes, and the noncanonical NF-κB pathway by up-regulating NIK, which, as a target of cIAP1 and cIAP2 ubiquitination/degradation ([@bib14]), is stabilized by their loss. TNFα is produced as a consequence of NF-κB activation (and presumably other signals) and binds TNF-R1. cIDE renders cells sensitive to TNFα alone because it facilitates release of RIP from the liganded TNF-R1 and the formation of an active and c-FLIP--resistant RIP--FADD--caspase-8 complex ([@bib17]). Given that CYLD-mediated deubiquitination of RIP seems to be important for this process, it is possible that cIAPs antagonize RIP release by countering deubiquitination or that they ubiquitinate and target RIP for destruction and, thus, a reduction in cIAP levels would enhance the formation of the death initiator complex. It remains puzzling why primary cells, despite TWEAK-induced loss of cIAP1, are resistant to TNFα. Another question is, how are cIAP1 and TRAF2 marked for lysosomal destruction? The fact that proteasomes are not involved does not rule out ubiquitination as the flag because ubiquitination can target proteins to lysosomes ([@bib13]). As with all surprising and provocative observations, there are many more questions than answers, but the emerging theme that down-regulating cIAP levels has profound effects on tumor cell survival may ultimately prove to be profoundly useful.

Figure 1.**cIDE signaling: pathways leading to and emanating from cIAP reduction in sensitive tumor cells.** (A) Under steady-state conditions, cIAP1/2 ubiquitinates NIK with K48-linked chains, maintaining it and noncanonical NF-κB signaling at low levels. cIAP1/2 also prevents spontaneous association of RIP with preexisting TNF-R1--assembled trimers. The ability of death domainless TNFRSF members like CD30 and CD40 to kill by cIDE has not been directly examined but is indirectly supported by the finding that CD30 signaling can cause TRAF2 degradation ([@bib3]). (B) Stimulation results in cIAP autoubiquitination and degradation in either proteasomes (TNFα/TNF-R2 or IAP antagonists) or lysosomes (TWEAK/FN14). TRAF2 is also degraded after receptor-mediated but not IAP antagonist stimulation. This results in NIK stabilization and increases in noncanonical NF-κB activation and recruitment of RIP to TNF-R1 leading to canonical NF-κB activation. TNFα is produced and exported to the membrane and secreted. (C) TNFα binds to and signals via TNF-R1. In the absence of cIAP, receptor-associated RIP is deubiquitinated by CYLD and does not gain K48-linked polyubiquitin, leaves the receptor, and assembles a death-initiating complex with FADD and caspase-8.

[^1]: Correspondence to Jonathan Ashwell: <jda@pop.nci.nih.gov>
